



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re patent application of:

Brunner, Hans R.

Appl. No.: 10/612,338

Filed: July 3, 2003

For: **Compositions and Methods Involving  
the Combination of a Thromboxane  
A2 Receptor Antagonist and an Inhibitor  
of Cyclooxygenase-2**

Art Unit: to be assigned

Examiner: to be assigned

Atty. Dkt.: 7571/80526

**Information Disclosure Statement**

Commissioner of Patents  
U.S. Patent and Trademark Office  
2011 South Clark Place  
Customer Window, **MS Missing Parts**  
Crystal Plaza Two, Lobby, Room 1B03  
Arlington, VA 22202

Sir:

Submitted herewith is a listing of documents known to Applicant and/or his attorney in compliance with the requirements of 37 C.F.R. § 1.56. One of these references was cited in the Search Report for corresponding international application no. PCT/IB03/02633 mailed September 19, 2003, a copy of which is enclosed. Copies of the listed documents are also enclosed.

Applicant does not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the present application. This statement should not be construed as a representation that more material information does not exist or that an exhaustive search of the relevant art has been made.

Consideration of the cited documents and making the same of record in the prosecution of the above-captioned application are respectfully requested.

Applicant does not believe any fee is due for the submission of this Information Disclosure Statement. However, the Commissioner is hereby authorized to charge any fee deficiency to our Deposit Account No. 06-1135 under Order No. 7571/80526.

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

By Michael A. Sanzo  
Michael A. Sanzo  
Reg. No. 36,912  
Attorney for Applicant

Date: November 25, 2003  
1801 K Street, N.W., Suite 401L  
Washington, DC 20006-1201  
Phone: (202) 419-7013

<b>LIST OF REFERENCES CITED BY APPLICANT</b> <small>(Use separate sheets if necessary)</small>				Atty. Docket No.: 7571/80526		Appl No.: 10/612,338	
				Applicant(s) Brunner, Hans. R.			
				Filing Date: July 3, 2003		Group: to be assigned	

OIPF 2003  
 NOV 26 2003  
 PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	AA 1	5,100,889	Mar. 31, 1992	Misra, <i>et al.</i>	514	365	Jun. 18, 1990
	AB 1	5,597,848	Jan. 28, 1997	Ito, <i>et al.</i>	514	539	Mar. 16, 1995
	AC 1	5,618,941	Apr. 8, 1997	Dickinson, <i>et al.</i>	546	249	Mar. 15, 1995
	AD						
	AE						
	AF						
	AG						

FOREIGN PATENT DOCUMENTS								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	AH 1	WO 01/87343 A2	Nov. 22, 2001	WIPO	A61K	45/06		
	AI							
	AJ							
	AK							

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)		
	AL 1	BOLTEN, "Scientific Rationale for Specific Inhibition of COX-2," <i>J. Rheumatol.</i> 25(51):2-7 (1998).
	AM1	GRISWOLD, <i>et al.</i> , "Constitutive Cyclooxygenase (COX-1) and Inducible Cyclooxygenase (COX-2): Rationale for Selective Inhibition and Progress to Date," <i>Med. Res. Rev.</i> 16(2):181-206 (1996).
	AN 1	LANE, "Pain Management in Osteoarthritis: The Role of COX-2 Inhibitors," <i>J. Rheumatol.</i> 24(49):20-24 (1997).
	AO 1	LIPSKY, <i>et al.</i> , "Outcome of Specific COX-2 Inhibition in Rheumatoid Arthritis," <i>J. Rheumatol.</i> 24(49):9-14 (1997).
	AP 1	MUKHERJEE, <i>et al.</i> , "Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors," <i>JAMA</i> 286:954-959 (2001).
	AQ 1	ROSENFELD, <i>et al.</i> , "Ifetroban Sodium: An Effective TxA <sub>2</sub> /PGH <sub>2</sub> Receptor Antagonist," <i>Cardiovascular Drug Rev.</i> 19(2):97-115 (2001).
	AR 1	VANE, <i>et al.</i> , "Mechanism of Action of Nonsteroidal Anti-inflammatory Drugs," <i>Am. J. Med.</i> 104(3A):2S-8S (1998).
	AS	

Examiner	Date Considered
----------	-----------------